Search research articles
Contact Us
Filters
Showing results (101-110 of 183) with videos related to
Page
of 19
Sort By:
Journal of Pharmaceutical and Biomedical Analysis
|
November 1, 1993
Determination of intoplicine, a new antitumour drug, in human faeces by normal-phase high-performance liquid chromatography with fluorescence detection
R van Gijn, S Kuijs, H Rosing, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
June 9, 2018
Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine
L van Andel, H Rosing, R Lubomirov, et al.
Pharmacological Research
|
June 24, 1999
Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion
V R Panday, W W ten Bokkel Huinink, J B Vermorken, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
June 24, 2009
Identification and profiling of circulating metabolites of atazanavir, a HIV protease inhibitor
R ter Heine, M J X Hillebrand, H Rosing, et al.
Anti-Cancer Drugs
|
January 6, 2001
Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration
M M Malingré, J H Schellens, O van Tellingen, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1995
Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks
L J van Warmerdam, J Verweij, J H Schellens, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
January 9, 2009
Quantification of the HIV-integrase inhibitor raltegravir and detection of its main metabolite in human plasma, dried blood spots and peripheral blood mononuclear cell lysate by means of high-performance liquid chromatography tandem mass spectrometry
R Ter Heine, M J X Hillebrand, H Rosing, et al.
American Journal of Clinical Oncology
|
July 28, 2001
Pharmacologic study of paclitaxel administered with or without the cytoprotective agent amifostine, and given as a single agent or in combination with epirubicin and cisplatin in patients with advanced solid tumors
J Van den Brande, V R Nannan Panday, K Hoekman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 1995
Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion
L J van Warmerdam, W W ten Bokkel Huinink, S Rodenhuis, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
April 2, 2013
Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography-tandem mass spectrometry
A Kort, M J X Hillebrand, G A Cirkel, et al.
Page
of 19
Search research articles
Search
Showing results (101-110 of 183) with videos related to
Sort By:
Page
of 19
Journal of Pharmaceutical and Biomedical Analysis
|
November 1, 1993
Determination of intoplicine, a new antitumour drug, in human faeces by normal-phase high-performance liquid chromatography with fluorescence detection
R van Gijn, S Kuijs, H Rosing, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
June 9, 2018
Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine
L van Andel, H Rosing, R Lubomirov, et al.
Pharmacological Research
|
June 24, 1999
Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion
V R Panday, W W ten Bokkel Huinink, J B Vermorken, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
June 24, 2009
Identification and profiling of circulating metabolites of atazanavir, a HIV protease inhibitor
R ter Heine, M J X Hillebrand, H Rosing, et al.
Anti-Cancer Drugs
|
January 6, 2001
Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration
M M Malingré, J H Schellens, O van Tellingen, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1995
Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks
L J van Warmerdam, J Verweij, J H Schellens, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
January 9, 2009
Quantification of the HIV-integrase inhibitor raltegravir and detection of its main metabolite in human plasma, dried blood spots and peripheral blood mononuclear cell lysate by means of high-performance liquid chromatography tandem mass spectrometry
R Ter Heine, M J X Hillebrand, H Rosing, et al.
American Journal of Clinical Oncology
|
July 28, 2001
Pharmacologic study of paclitaxel administered with or without the cytoprotective agent amifostine, and given as a single agent or in combination with epirubicin and cisplatin in patients with advanced solid tumors
J Van den Brande, V R Nannan Panday, K Hoekman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 1995
Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion
L J van Warmerdam, W W ten Bokkel Huinink, S Rodenhuis, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
April 2, 2013
Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography-tandem mass spectrometry
A Kort, M J X Hillebrand, G A Cirkel, et al.
Page
of 19